sofituzumab vedotin sofituzumab vedotin sofituzumab vedotin (inn; development code dmuc5754a) is a monoclonal antibody designed for the treatment of ovarian cancer. sofituzumab vedotinmonoclonal antibodytype?sourcehumanized (from mouse)targetcarbohydrate antigen 125clinical dataother namesdmuc5754aatc codenoneidentifierscas number1418200-58-4chemspidernoneunii2x3ckg601lkeggd11241chemical and physical datamolar mass144.7 kg/mol this drug was developed by genentech/roche. sofituzumab vedotin is an antibody-drug conjugate that targets muc16, a protein that is overexpressed in several types of cancer including ovarian and pancreatic cancer. the conjugate consists of a human anti-nectin-4 antibody linked to the cytotoxic agent mmae, which is released after internalization by the cancer cell. in addition to its direct cytotoxic effect, sofituzumab vedotin may also mediate antitumor activity through signal transduction inhibition, antibody-dependent cellular cytotoxicity, and complement-dependent cytotoxicity. clinical trials have shown promising results in the treatment of ovarian and pancreatic cancer.